๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mesoblast Limited (ASX:MSB)
Australia flag Australia ยท Delayed Price ยท Currency is AUD
1.695
-0.010 (-0.59%)
Nov 20, 2026, 4:10 PM AEDT
โ† View all transcripts

Bell Potter Healthcare Conference

Nov 18, 2026

Summary

FY26 revenue reached $115M, while RYONCIL expanded commercially and adult GVHD and Duchenne programs advanced. A 350-patient low-back-pain trial is expected to read out around mid-2027; cardiovascular plans include a potential LVAD-related filing and pulmonary hypertension development.

John Hester
Analyst, Bell Potter

Good morning and welcome back. Our next guest hardly needs an introduction. Dr. Silviu Itescu is the Chief Executive Officer of Mesoblast, and arguably the driving force behind the registration of the first-ever FDA-approved stem cell therapy product. Joining Silviu this morning is Head of Investor Relations, Paul Hughes. Thank you, gentlemen, for joining us.

Paul Hughes
Head of Investor Relations, Mesoblast

Thanks, John.

Silviu Itescu
CEO, Mesoblast

No worries.

John Hester
Analyst, Bell Potter

The approval of RYONCIL was a pivotal moment in the company's evolution, as revenues from sales have since funded the ongoing clinical development program. Over the course of the next 12 months, Mesoblast is expecting headline data from its second phase III randomized clinical trial in chronic low back pain, in addition to completion of enrollment of the randomized clinical trial for RYONCIL in treatment of graft-versus-host disease. Preceding those events, Mesoblast expects to lodge a biologics license application for its second product, being rexlemestrocel-L, and we will come to that in just a moment. But for now, Silviu and Paul, great to have you with us, and thank you for joining us.

Silviu Itescu
CEO, Mesoblast

Thank you.

John Hester
Analyst, Bell Potter

Now, Silviu, let's start with the deck, and we'll come back and have some questions as you're going along. So why don't you take it away?

Silviu Itescu
CEO, Mesoblast

Terrific. Thank you. Let me give everybody a bit of an overview of where we are as a company. We had a great fiscal year 2026. Here are some of the highlights. We had net revenues of $115 million and a gross profit, excluding amortization expenses, of $110 million. We achieved some major milestones in the year. First of all, we completed treatment of 350 patients in the pivotal phase III trial for our blockbuster chronic low back pain indication. That was a momentous endpoint. And those patients are being followed for 12 months, and that 12 months will be in around mid-year this calendar year 2027, when we read out the primary endpoint. Primary endpoint of the trial is, did we reduce pain from a single injection into the disc relative to placebo over a 12-month period?

We did in an earlier phase III trial, and so we hope to confirm that same outcome in this program. Secondly, we had a very good meeting with the FDA, where we aligned on getting a green light to file for approval of our product, rexlemestrocel-L, for end-stage heart failure patients, and that is an ultra-orphan indication, but it has major implications for large, again, blockbuster indications in heart failure with reduced ejection fraction. We've also commenced a registration trial for label extension of RYONCIL from children into adults with steroid-refractory graft-versus-host disease. It's enrolling patients, and we target to have up to 40 sites up across the U.S. by the end of December. We're targeting to have about, I think, 20 sites or so up and running.

Another indication that we are focusing on is a very rare disease with children with inflammation of the muscles called Duchenne's muscular dystrophy, and a phase III trial has been cleared by the FDA during the course of the year to begin during the course of 2027. And finally, we entered into a $125 million five-year non-dilutive credit line facility, which cleaned up and consolidated and retired two higher-cost facilities that were already in place. Next slide, please. Now, we have a moat, an important concept which separates us from the rest of the pack and puts us in a market leadership position. We have patents, over 1,100 patents, global portfolio, which provide commercial protection for our products through beyond 2044.

We have a dominant patent estate which protects us both the products, the way we manufacture them, how we use them for every indication, so it's a broad patent estate. We have a first-mover advantage by being the only company to have an FDA-approved product, an allogeneic off-the-shelf stem cell, which we call RYONCIL. It's a big deal, and we don't see competitors on the horizon. We seek to leverage that approval beyond the first indication. I've given you some sense of the adult indications and other pediatric rare diseases for which a label can be extended. We've completed multiple randomized controlled trials which underpin the efficacy of our product and demonstrate proven evidence of efficacy across our platforms.

We are also a first-in-class leader in manufacturing, so we've had to invent, if you like, by being the first in this space, a supply chain from start to finish, which we've got under control from the manufacturing side to transportation, to warehousing, to cold chain storage, to cold chain distribution, to the end user. That is a very important and valuable know-how that allows us to leverage across multiple products as we develop them now. Finally, we've got next-generation technology leadership that we've brought in, genetic modification of our cells to potentially enhance potency, the tissue homing characteristics for, again, larger markets in the inflammatory disease space. We also have an executive leadership team with proven capability to bring our cell therapy products to market. We've demonstrated we can do it, and we'll do it again. Next slide, please.

This slide shows you the pillars, the three pillars on which we've built this company. RYONCIL now is our first FDA-approved product. It's had a successful first year of launch with solid revenues, probably revenues that were beyond most people's expectations. The basis for that is our commercial capability and the infrastructure that we've built that has been based on the number of centers onboarded, more than 50 to date. The ability to bring on commercialization through insurance coverage, more than 98% of commercial insurance coverage exists across the U.S. 98% of all lives covered by commercial insurance now cover RYONCIL. Finally, bringing on board government payers, Medicare, Medicaid. We got a J-Code last October, so that in conjunction with the fact that Medicaid mandates all states in the U.S. to reimburse RYONCIL.

The J-Code tells them how much they should reimburse, which is at the WAC price plus a small margin. Finally, our 2nd generation product, rexlemestrocel-L, is the third pillar, which is the engine for our blockbuster opportunities. Those blockbuster large market opportunities, as opposed to RYONCIL for GVHD, include multi-billion dollar potential areas such as chronic low back pain and cardiovascular disease, particularly the newer area that we're focusing on, which is pulmonary hypertension as a complication of HFrEF. Next slide, please. This is a snapshot of our pipeline, and you can see where some of our products are already commercial, some are in phase III, and some are in phase II, but they're all late stage and beyond. RYONCIL in black is our 1st generation platform. The pediatric product is in the market.

The adult product is in phase III, and the Duchenne's is about to commence phase III. The total addressable market for RYONCIL is therefore north of $2 billion. But the real opportunity for the total addressable markets of more than $10 billion per indication is for rexlemestrocel-L, a next-generation product being developed for multiple cardiovascular indications and for chronic refractory pain, the first of which is chronic low back pain. More about each of these in detail, I am sure, during the course of this discussion. Next slide, please. Perhaps this is a good time just to say one snapshot about our adult trial for GVHD. This is the potential to extend the RYONCIL franchise from children to adults. The adult market is about 3x or 4x the size of the pediatric market that we are targeting.

A randomized controlled trial of up to 180 patients is ongoing. Potentially, we could have an early read after 100 patients are done. The objective of that would be to achieve that by the end of the next calendar year. If we exceed the targeted number for superiority, we would stop and call success and file with the FDA for label extension. If we do not meet the higher threshold for success, we will continue to 180 patients.

John Hester
Analyst, Bell Potter

Silviu, can I just jump in there?

Silviu Itescu
CEO, Mesoblast

Yeah.

John Hester
Analyst, Bell Potter

There is adult data in the market. There was an investigator-sponsored trial from a couple of years ago.

Silviu Itescu
CEO, Mesoblast

Yeah.

John Hester
Analyst, Bell Potter

This is a really important trial for RYONCIL because it is a randomized study in adults. It is the first big randomized study that the company has conducted in this population. Let us just revisit that data from the investigator-sponsored trial from a few years ago. This is Joanne Kurtzberg's work at Duke. Can we revisit that data for a second?

Silviu Itescu
CEO, Mesoblast

Sure. Look, there are several pieces of data, actually. Joanne Kurtzberg primarily did work with children, and then separate from the data with children under her investigational IND, the company actually opened an adult compassionate care IND, where we collected data on about, I think, 53 adults. Looking at those data together, particularly the adults, is where we got most of our exciting data. Joanne Kurtzberg looked at children, third-line treatment, and in her study, and she has published those studies, basically the results there were that RYONCIL, the new improved RYONCIL product, substantially improved survival over the old Prochymal product. That was a very important finding, which gave us a lot of confidence that the manufacturing superiority and the potency superiority of RYONCIL would fly over from children to adults.

Because if you might recall, many years ago, the old product, Prochymal from Osiris, actually failed a phase III trial in adults. The data in children in third line allowed us to go to an expanded access program in adults. The company ran that study, and in 53 patients who had otherwise failed second-line therapy, predominantly ruxolitinib, we saw a survival outcome of about 76%. That survival outcome was stunning in adults because the expected survival in patients who failed ruxolitinib is on the order of 25% at three months. Those data tell us that we can rescue the sickest of the sick patients. When we spoke with the FDA and showed them these data, the FDA nonetheless said, "Well, we like it.

I think it is great, but you need to do a randomized control trial and prove that against controls," which, as I said to you, controls in this population have a 25% survival. Then you have got the basis for an approval. We talked to the physicians who run the Blood and Marrow Transplant CTN network, and they just said that it is just not feasible. They are not prepared to put their patients that sick into a controlled trial because they want their patients to have access to anything that potentially could save their lives. I think that kind of a trial is just too difficult to perform.

We went back to the FDA with these investigators and proposed a randomized control trial in the next, not quite a sick population, but population that is not doing very well on ruxolitinib, which is second line, where ruxolitinib in grade three, four disease only gets about a 40%-50% responder rate.

We think the combo should give us about a 75% or more responder rate, right? By adding ourselves to ruxolitinib in those very sick patients, very high-risk patients, a second line, we expect to see the same sort of outcomes as we have just seen when those patients have failed ruxolitinib and are then rescued by us. That is the trial that we are doing. That way, the trial will enroll. The control arm we expect to not do very well, and we think that the treatment arm with our cells will boost the effect in patients who are otherwise destined to fail and die. That allows us to become part of the mainstream second-line treatment regimen, which then means that we can access many more patients in second-line GVHD adults.

Paul Hughes
Head of Investor Relations, Mesoblast

Okay, let us keep going. We are running. We will keep going.

Silviu Itescu
CEO, Mesoblast

Sure. Let us move on to Rex, the 2nd generation product. You have touched on this, and I have touched on this. We have a big year coming up. Next slide, please. What is this disease? In the intervertebral disc, you can see there on the left, on the schematic on the left in blue, a nice healthy disc serves like a little cushion between the vertebra above and the vertebra below, so that when you walk, when you run, when you exercise, you are fully mobile. With age, with trauma, that healthy little disc starts to crack, and as it cracks, it undergoes inflammation. On the right-hand side of that picture, the red denotes the inflammatory process in the middle of the disc. Lots of immune cells. Our approach is to inject directly into that disc space a tiny number of our cells, of rexlemestrocel-L cells.

And in previous phase II and a more recent phase III trial, a single injection of our cells resulted in at least 12-month substantial improvement in pain, and actually, substantial improvement for at least three years. In fact, 50% of patients by 12 months and up to three years have no pain at all, despite being very severe in their chronic debilitating pain for at least six months before they got into our studies. The current phase III trial that is ongoing has enrolled and treated 350 patients, randomized controlled one-to-one. Primary endpoint will be the 12-month readout middle of next year. If positive, we are obviously completing commercial manufacturing in the same timeframe, and so we will be able to aim for a filing by the end of next year or shortly thereafter for full approval.

The FDA has given us a green light that if it is positive, this product is in line for full approval. Next slide, please. So, what is the patient journey, and do we understand who our patients are? There is probably about 7 million people in the U.S. affected by severe inflammatory disc disease for whom conservative treatments have failed. By conservative, I mean all of the stuff in the left column, non-steroidal anti-inflammatory drugs, physical therapy, et cetera. Often, they even get epidural steroids very early, and those work for a short amount of time, but really ultimately do not work. Really, most of these patients have one choice, and that is to have opioids. Opioids either do not work very well or are associated, because of the fact they do not work well, with people being hooked and taking higher and higher doses.

And we are all aware of the 100,000 patients who die because of accidental overdosing in the U.S., real epidemic of this. So, opioids are on the way out and shouldn't be used broadly. With that not an option, all we have is interventional therapies and surgery. So these patients are a large unmet need. The end users who look after them are pain doctors and general practitioners, and these physicians are pleading to have new approaches to treat these patients. Next slide, please. Before we go to the cardiovascular, I would say that having gone through a survey of our results from the first trial, and we put those results in front of pain physicians who treat these very patients, 85% of them say that they would use the drug based on the results they have already seen to date.

So, we can talk more about our approach to distribution, commercialization, et cetera. There are many ways by which we reach the end user. It will be through existing networks, through potential strategic alliances, or through surgical clinics where patients currently go to have various procedures done. So there are many ways by which the product will be distributed, and we will address those once the readout is positive. John, do you have any questions about the back pain that you would like to address now before we move to cardiac?

John Hester
Analyst, Bell Potter

No. Silviu, I think that, look, let's just move on to the cardiac piece.

Silviu Itescu
CEO, Mesoblast

Sure.

John Hester
Analyst, Bell Potter

I'll come back and have a couple of general questions more about Rex after you've done the cardiac piece. Thanks, Silviu.

Silviu Itescu
CEO, Mesoblast

Good. Okay, next slide, please. The cardiac franchise is basically outlined here, where we start on the left-hand side with the very end-stage patients who are being kept alive on an LVAD, but they have severe inflammation, and the complications of inflammation there are bleeding from the gut, in particular, which is life-threatening and which we've reduced substantially and would be the basis for an initial approval. In the middle, you see the traditional class II/III heart failure population, which we've completed a 565-patient randomized controlled trial and reduced the risk of heart attacks, strokes, and deaths. On the right-hand side, the new area where a subgroup, a substantial subgroup of the heart failure population, maybe up to 35% to 40%, actually die because they have backup of pressure in their lungs and they get pulmonary hypertension.

It's cardiopulmonary disease, and these patients have a very high mortality. Maybe 50% die within three years. This is a group that, as the trial has now gone on longer and we've followed up the patients longer, we can now see that a substantial number of patients, a large proportion of patients die of pulmonary hypertension, and it's these patients that we now have seen we can make a major impact on, particularly protecting them against this complication and reducing cardiac mortality. Huge unmet need. There are no drugs approved for this complication, and we think we can make a major impact here. All of the spectrum of cardiovascular disease that we think rexlemestrocel-L can address all are based on a common mechanism of action.

They are all driven by inflammation, they are all driven by endothelial dysfunction and vascular disease, and all of them are reversed through our cells' interaction with the inflammatory cells, turning them off, and that results in substantial clinical outcome benefits in each of these areas. Next slide, please. With respect to the LVAD population, this table just gives you a snapshot of the real risk. These patients end up with a substantially higher risk of major life-threatening bleeding. This is not small-time bleeding. It is huge bleeding episodes requiring transfusions and hospitalizations, and often resulting in death. A single injection into the myocardium of our cells reduces bleeding by between 6-8 -fold. Very significant P-value. We have had a meeting with the FDA on this as an endpoint for approval, and the FDA has greenlighted us to move forward with a potential filing.

John Hester
Analyst, Bell Potter

Silviu, I might just jump in there with a question, if I may.

Silviu Itescu
CEO, Mesoblast

Yeah.

John Hester
Analyst, Bell Potter

Just on rexlemestrocel-L, same drug, two very large but very different indications. But essentially what the drug is, one heck of an anti-inflammatory. But the board has decided to go ahead and lodge the BLA for the first indication in patients with end-stage heart failure and with an LVAD device and life-threatening GI bleeding. That indication also has orphan disease designation. And earlier this year, the company made an announcement regarding some guidelines from the FDA with regard to concessional treatment for just this sort of indication. You have taken that all in and decided to go with the heart failure indication first, ahead of the much larger, probably, back pain indication. Have I got that right? And is that strategy-

Silviu Itescu
CEO, Mesoblast

Yeah, I think it is important that we walk you through exactly the strategy.

John Hester
Analyst, Bell Potter

Yeah.

Silviu Itescu
CEO, Mesoblast

The FDA's flexibility applies in two ways, potentially. One is on clinical trials, and two is on manufacturing. With respect to clinical trial flexibility, they've moved from needing, in the old days, they always required two randomized controlled trials to replicate each other for big diseases, right? For high-volume diseases. They've shown flexibility, and they've put in writing that they've got flexibility to move to a single trial when the outcomes are mortality-related. With respect to back pain, obviously that's an important endpoint in terms of pain reduction, but it's not a mortality-related disease. That's why we're actually completing a second randomized controlled trial, so that there's no question around the totality of the data that we'll put in front of the FDA.

John Hester
Analyst, Bell Potter

Yeah.

Silviu Itescu
CEO, Mesoblast

With respect to cardiovascular disease, there are two issues here. One is the LVAD population is an orphan disease. The bigger heart failure population is not an orphan disease. The advantage of going first with the LVAD population is that we've completed one large randomized controlled trial where we showed a significant reduction in bleeding, and bleeding is the biggest endpoint to date that that population suffers from, especially because it's often related to death. The point of the discussion with the FDA and the board is considering is that given that there's only one trial required, we can go forward with a filing for approval of that drug for that indication.

If we want to move forward with a label for the broader heart failure population, pulmonary hypertension being probably the most valuable endpoint in heart failure that we can address right now because there are no competitors in that space. We haven't yet had a discussion with the FDA, but we think that a single trial would support approval for that indication. We've had an earlier meeting with the FDA where, in fact, a single trial for the broader population of class II/III heart failure with three-point MACE reduction would be sufficient for approval with that as an endpoint. But we haven't yet had the same discussion on pulmonary hypertension. I suspect that they will be comfortable with one more trial for approval.

John Hester
Analyst, Bell Potter

Okay.

Silviu Itescu
CEO, Mesoblast

But I think the flexibility relates to one trial versus two trials for big diseases or for orphan diseases. With respect to flexibility on manufacturing, that's a separate flexibility component of the new FDA, if you like. Again, you can get flexibility on how you present your manufacturing dossier if you're going for an orphan indication, whereas if your indication that you're going for is broader, non-orphan, they expect a more robust manufacturing package. One of the discussions we're having right now internally is whether we go with the LVAD filing with a manufacturing package that is abbreviated- that would also support partially the back pain product. But in fact, the back pain manufacturing requires more because it's a non-orphan indication.

Those are the components sitting behind our timing for both the LVAD filing and the back pain filing. How much of the manufacturing is needed to support the two indications? Potentially less robust for the orphan indication, more robust for the broader indication. Does that make sense?

John Hester
Analyst, Bell Potter

Yeah, that's a good summation. We're running out of time, Silviu, so let's just move through the rest of the deck, and we'll come back and wrap it up.

Silviu Itescu
CEO, Mesoblast

Yeah, I think we've only got one slide to go, don't we, Paul?

John Hester
Analyst, Bell Potter

Okay.

Silviu Itescu
CEO, Mesoblast

Maybe we go very fast through the pulmonary hypertension story.

John Hester
Analyst, Bell Potter

Yeah.

Silviu Itescu
CEO, Mesoblast

The pulmonary hypertension story is exactly what I said. On the left-hand side is what happens when you have inflammatory heart failure. The left heart starts to fail. As it fails, the pressure goes back into the lungs. As it goes into the lungs, it puts greater pressure on the right side of the heart, and the right side fails, and the patients have a high mortality due to right heart failure. Next slide. What we found now as we followed our 560-patient trial long enough is, in fact, we now know that 35%-40% of the patients had pulmonary hypertension at baseline as measured by echo. And in those patients, we see a high mortality from right heart failure. But surprisingly, we see that a single injection of our cells has reduced cardiac death from right heart failure by 53%.

It's a remarkable outcome, and it opens a market that is potentially half a million patients in the U.S. suffer from pulmonary hypertension due to low ejection fraction heart failure, and another 0.5 million from normal ejection failure, not normal ejection heart failure populations, which is another large unmet medical need. Next slide, please. And that's where we see that there's about 1.1 million patients in the U.S. who suffer with this disease and have no approved drugs. Next slide. We've touched on the next-generation technologies. I'm not going to say anything more about them now other than we brought in some pretty exciting stuff from the Mayo Clinic, which allows us to put genetically modified CARs on the surface of our cells, enhancing their homing characteristics, increasing their potency, and giving us the potential to create new products as next-generation products come along.

John Hester
Analyst, Bell Potter

Yeah, Silviu, we'll have to wrap it up there, but I would have loved to have had the time to ask more questions about this program in particular. There's a lot of work going on around the world with CARs and inflammatory disease, particularly in lupus, not to mention inflammatory lupus, rather, and also in inflammatory bowel disease. But we'll save that for another day. Can't wait to see some first data from that. Thank you both very much for your time this morning. We are going to have to cut it off there.

Silviu Itescu
CEO, Mesoblast

Perfect.

John Hester
Analyst, Bell Potter

But look, it's been a great run-through. Thank you very much.

Silviu Itescu
CEO, Mesoblast

Thanks for having us. Appreciate it.

John Hester
Analyst, Bell Potter

You're welcome, Silviu. Thank you, Paul Hughes. Okay, thank you very much. We'll go to a short break.